Select region

Subscribe to our news feed


A question?

NAVA – a gamechanger for neonatal care in Slovakia

When using Getinge’s patented Neurally Adjusted Ventilatory Assist (NAVA) with diaphragm monitoring (Edi) for the first time in 2021, it soon became clear to the neonatal team in the F.D. Roosevelt University Hospital in Banska Bystrica, Slovakia, that the solution would become a gamechanger for their treatment of premature babies.

Getinge invites fund managers, analysts, and media to Q1 Report 2024 conference call

Getinge will issue its Q1 Report 2024 on April 22, 2024, at 12:00 p.m. CEST, followed by a conference call at 13:00-14.00 p.m. CEST, hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.

Getinge extends the bioreactor portfolio with larger single-use systems

Getinge is extending its bioreactor offering by introducing the Single-Use Production Reactor (SUPR) system, which initially is available in 50-liter and 250-liter sizes. Based on the same proven platform as Getinge’s smaller bioreactors, the SUPR system helps operators to bring life-saving medicines faster to market, aiming to improve people’s quality of life.

Getinge donates life-saving medical equipment to Ukraine

In a time where medical assistance is critical, Getinge donates extensive medical equipment to Ukraine. The donation, made in collaboration with the Ministry of Health Ukraine, includes a significant number of anesthesia machines and ventilators, aimed at directly improving healthcare and increasing the country's resilience against the challenges of war.

Getinge publishes 2023 annual report

Today, Getinge publishes its 2023 annual report including a sustainability report, summarizing a year of huge contrasts. The global medtech company’s 2023 was marked by record-breaking sales, two major acquisitions, and successful product launches, amid the continued war in Europe, quality challenges in two product segments, and persistent inflationary pressure.

Getinge and CellRev launch platform with potential to transform allogeneic cell therapy manufacturing

Getinge has partnered with the bioprocessing company CellRev in the development of a continuous cell processing platform called Livit ACE (Adherent Cell Expansion). The solution, launching today, is a breakthrough within allogenic cell therapy manufacturing.

Press Contacts

Jeanette Hedén Carlsson

EVP Brand & Communication
Phone: +46 10 335 1003

Anna Appelqvist

Vice President Corporate Communications
Phone: +46 10 335 5906


Prefer to contact us online

Click below to fill in the appropriate form. We will be in touch shortly.

Are you looking for

Getinge Hybrid OR

Image Gallery

Diverse picture format made available for press article purpose 

Man and woman looking a something together

About us

All you need to know about Getinge a one glance


Urgent Medical Device Correction

Voluntary Urgent Medical Device Field Correction for the CARDIOSAVE intra-aortic balloon pump (IABP)


Don't miss anything

Click on the icons and follow us!